Archives
Rucaparib (AG-014699): Potent PARP1 Inhibitor for DNA Dam...
Rucaparib (AG-014699, PF-01367338): Potent PARP1 Inhibitor for DNA Damage Response Research
Executive Summary: Rucaparib (AG-014699, PF-01367338) is a potent PARP1 inhibitor with a Ki of 1.4 nM, primarily used for DNA damage response and cancer biology research (bioRxiv preprint). Its radiosensitizing effects are specific to PTEN-deficient and ETS gene fusion-expressing prostate cancer cells (internal evidence). Rucaparib induces persistent DNA breaks through inhibition of non-homologous end joining (NHEJ), as evidenced by increased γ-H2AX and p53BP1 foci formation (site article). The compound’s oral bioavailability and brain penetration are modulated by ABC transporters. APExBIO supplies Rucaparib (A4156) as a solid compound, soluble at ≥21.08 mg/mL in DMSO, recommended for storage at –20°C (product page).
Biological Rationale
Poly (ADP ribose) polymerase 1 (PARP1) is a nuclear enzyme activated by DNA damage. It is central to the base excision repair (BER) pathway, responsible for repairing single-strand DNA breaks. Inhibition of PARP1 by Rucaparib leads to the accumulation of unrepaired DNA breaks, triggering cell death, especially in cells with deficient homologous recombination or non-homologous end joining (NHEJ) pathways (bioRxiv preprint). PTEN-deficient and ETS gene fusion-expressing prostate cancer cells are particularly susceptible, as they already exhibit impaired DNA repair capacity. This mechanistic vulnerability underpins Rucaparib’s radiosensitizing effect, making it a valuable probe for DNA damage response research and precision oncology (internal article).
Mechanism of Action of Rucaparib (AG-014699, PF-01367338)
Rucaparib is a competitive inhibitor of PARP1, binding with a Ki of 1.4 nM. Upon inhibition, PARP1 is unable to poly-ADP ribosylate target proteins, leading to impaired recruitment of DNA repair machinery. In cells exposed to genotoxic agents, such as irradiation, Rucaparib induces radiosensitization by blocking repair of single- and double-strand DNA breaks. This is evidenced by the persistence of γ-H2AX and p53BP1 foci, markers of DNA double-strand breaks (bioRxiv preprint). Rucaparib’s effect is potentiated in PTEN-deficient and ETS gene fusion-expressing models, where NHEJ repair is already compromised. The compound’s transport and oral availability are modulated by ABCB1 and other ABC transporters, impacting brain penetration and systemic exposure (site review).
Evidence & Benchmarks
- Rucaparib inhibits PARP1 with a Ki of 1.4 nM under standard biochemical assay conditions (pH 7.4, 25°C) (APExBIO).
- In PTEN-deficient, ETS gene fusion-expressing prostate cancer cells, Rucaparib increases radiosensitivity, evidenced by a >2-fold rise in γ-H2AX foci after 2 Gy irradiation plus 1 μM Rucaparib, 24 hours post-treatment (bioRxiv preprint).
- Persistent p53BP1 foci are observed in Rucaparib-treated, irradiated cancer cells, indicating defective DSB repair capacity (site article).
- Rucaparib is a substrate of ABCB1; oral bioavailability and CNS penetration are reduced in the presence of active ABC transporters (mechanistic review).
- Recommended storage for the solid compound is –20°C; solutions in DMSO (≥21.08 mg/mL) are stable for several months at –20°C, but not suitable for long-term storage at room temperature (APExBIO).
Applications, Limits & Misconceptions
Rucaparib (AG-014699, PF-01367338) is an established research tool for interrogation of base excision repair, radiosensitization, and the study of synthetic lethality in cancer models with impaired DNA repair. Its use is especially relevant in PTEN-deficient and ETS gene fusion-expressing prostate cancer cell lines, where it synergizes with irradiation to induce cytotoxicity (internal article). The product is not suitable for all cancer models; its efficacy is highly dependent on the genetic context and DNA repair capacity of the cells under investigation. Oral and CNS applications are modulated by ABC transporter expression, which must be accounted for in experimental design. For a deeper mechanistic perspective, see this review, which benchmarks cell death mechanisms and translational potential. In contrast, the present article provides a granular, protocol-focused deployment framework.
Common Pitfalls or Misconceptions
- Rucaparib does not sensitize all tumor types—efficacy is limited in models with intact homologous recombination or proficient NHEJ (bioRxiv).
- Oral and brain delivery are significantly reduced in the presence of active ABCB1; experimental outcomes may vary based on transporter expression (site review).
- Stock solutions must be stored at –20°C; room temperature or repeated freeze-thaw cycles can degrade compound integrity (APExBIO).
- Rucaparib is insoluble in water and ethanol; DMSO is the only validated solvent for high-concentration stock preparation (APExBIO).
- Interpretation of γ-H2AX foci as a direct measure of cytotoxicity may be confounded by replication stress or checkpoint activation independent of cell death (site article).
Workflow Integration & Parameters
Researchers should prepare Rucaparib stock solutions at concentrations ≥21.08 mg/mL in DMSO, aliquot, and store at –20°C. Working concentrations range from 0.1 μM to 10 μM, depending on the cell line and endpoint. For radiosensitization assays, apply Rucaparib 1–2 hours prior to irradiation (2–6 Gy), maintaining exposure for up to 24–72 hours. Monitor DNA damage by quantifying γ-H2AX and p53BP1 foci via immunofluorescence. For in vivo models, consider co-administration with ABC transporter inhibitors if oral or CNS exposure is sought. For further details and advanced design, this guide examines experimental nuances; here we focus on standardized deployment and troubleshooting.
Conclusion & Outlook
Rucaparib (AG-014699, PF-01367338) is a validated, potent PARP1 inhibitor, essential for dissecting DNA damage response and radiosensitization in cancer models with impaired DNA repair. Its deployment requires strict attention to genetic context, compound handling, and solubility characteristics. As research advances, integration of Rucaparib with emerging cell death and repair paradigms, including RNA Pol II degradation pathways (bioRxiv), will expand its application. For researchers seeking detailed protocols or compound sourcing, APExBIO provides comprehensive product support and validated supply channels via the Rucaparib (AG-014699, PF-01367338) A4156 page.